A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics

Background:Timely diagnosis and classification of colorectal cancer (CRC) are hindered by unsatisfactory clinical assays. Our aim was to construct a blood-based biomarker series using a single assay, suitable for CRC detection, prognostication and staging.Methods:Serum metabolomic profiles of adenoma (N=31), various stages of CRC (N=320) and healthy matched controls (N=254) were analysed by gas chromatography-mass spectrometry (GC-MS). A diagnostic model for CRC was derived by orthogonal partial least squares-discriminant analysis (OPLS-DA) on a training set, and then validated on an independent data set. Metabolomic models suitable for identifying adenoma, poor prognosis stage II CRC and discriminating various stages were generated.Results:A diagnostic signature for CRC with remarkable multivariate performance (R2Y=0.46, Q2Y=0.39) was constructed, and then validated (sensitivity 85%; specificity 86%). Area under the receiver-operating characteristic curve was 0.91 (95% CI, 0.87–0.96). Adenomas were also detectable (R2Y=0.35, Q2Y=0.26, internal AUROC=0.81, 95% CI, 0.70–0.92). Also of particular interest, we identified models that stratified stage II by prognosis, and classified cases by stage.Conclusions:Using a single assay system, a suite of CRC biomarkers based on circulating metabolites enables early detection, prognostication and preliminary staging information. External population-based studies are required to evaluate the repeatability of our findings and to assess the clinical benefits of these biomarkers.

[1]  Joachim Selbig,et al.  The Golm Metabolome Database: a database for GC-MS based metabolite profiling , 2007 .

[2]  Rongwei Fu,et al.  Screening for Colorectal Cancer: A Targeted, Updated Systematic Review for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[3]  Stephen E. Stein,et al.  Chemical substructure identification by mass spectral library searching , 1995, Journal of the American Society for Mass Spectrometry.

[4]  D. Kerr,et al.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[6]  Russ Greiner,et al.  Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. , 2007, Analytical chemistry.

[7]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[8]  Yanlei Ma,et al.  An Integrated Proteomics and Metabolomics Approach for Defining Oncofetal Biomarkers in the Colorectal Cancer , 2012, Annals of surgery.

[9]  Tianlu Chen,et al.  Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. , 2009, Journal of proteome research.

[10]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[11]  Douglas N Rutledge,et al.  PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. , 2015, Molecular bioSystems.

[12]  Daniel Raftery,et al.  Colorectal cancer detection using targeted serum metabolic profiling. , 2014, Journal of proteome research.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[14]  Royston Goodacre,et al.  Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. , 2011, Chemical Society reviews.

[15]  F. Farshidfar,et al.  From Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer , 2014, Genes.

[16]  Eugene S. Edgington,et al.  Randomization Tests , 2011, International Encyclopedia of Statistical Science.

[17]  R. Rosenberg,et al.  Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study , 2014, British Journal of Cancer.

[18]  Joachim Thiery,et al.  Serum amino acid profiles and their alterations in colorectal cancer , 2011, Metabolomics.

[19]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[20]  B. Manns,et al.  Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation , 2010, PLoS medicine.

[21]  Eric Chun Yong Chan,et al.  Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry , 2012, Analytical and Bioanalytical Chemistry.

[22]  Julian L Griffin,et al.  Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. , 2006, Pharmacogenomics.

[23]  M. Zheng,et al.  Metabonomics identifies serum metabolite markers of colorectal cancer. , 2013, Journal of proteome research.

[24]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Vogel,et al.  Serum metabolomic profile as a means to distinguish stage of colorectal cancer , 2012, Genome Medicine.

[26]  P. Loehrer.  Lymph Node Evaluation in Colorectal Cancer Patients: A Population-Based Study , 2006 .

[27]  L. Sarli,et al.  Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. , 2005, European journal of cancer.

[28]  S. Fedewa,et al.  Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening , 2015, CA: a cancer journal for clinicians.

[29]  Tomasz Burzykowski,et al.  Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas? , 2002, Journal of surgical oncology.

[30]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[31]  M. Hirai,et al.  MassBank: a public repository for sharing mass spectral data for life sciences. , 2010, Journal of mass spectrometry : JMS.

[32]  Ivano Bertini,et al.  Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. , 2012, Cancer research.

[33]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[34]  R. Labianca,et al.  Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. , 2012, Journal of the National Cancer Institute.

[35]  S. Goodman,et al.  Counting alleles to predict recurrence of early-stage colorectal cancers , 2002, The Lancet.

[36]  H. Tanke,et al.  Prognostic relevance of occult tumour cells in lymph nodes in colorectal cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  J. Cubiella,et al.  Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[38]  Sridhar Ramaswamy,et al.  Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[40]  Rebecca M. Dodson,et al.  Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma? , 2013, Journal of the American College of Surgeons.

[41]  Oliver F Bathe,et al.  Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[42]  Douglas A. Wolfe,et al.  Nonparametric Statistical Methods , 1973 .

[43]  H. Senn,et al.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.

[44]  T. Takenawa,et al.  A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer , 2012, PloS one.

[45]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Vogel,et al.  An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. , 2007, Journal of proteome research.